Next earnings date: 27 Oct 2025
Novartis AG – NYSE:NVS
Novartis AG stock price today
$125.6
+27.20
+27.66%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 18 hours
Novartis AG stock price monthly change
-11.92%
month
Novartis AG stock price quarterly change
-11.92%
quarter
Novartis AG stock price yearly change
-1.32%
year
Novartis AG key metrics
Market Cap | 190.36B |
Enterprise value | 211.04B |
P/E | 11.24 |
EV/Sales | 4.28 |
EV/EBITDA | 10.67 |
Price/Sales | 3.90 |
Price/Book | 4.57 |
PEG ratio | -0.29 |
EPS | 7.42 |
Revenue | 49.63B |
EBITDA | 18.82B |
Income | 15.24B |
Revenue Q/Q | -10.44% |
Revenue Y/Y | -4.95% |
Profit margin | 35.71% |
Oper. margin | 27.93% |
Gross margin | 74.43% |
EBIT margin | 27.93% |
EBITDA margin | 37.93% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNovartis AG stock price history
Novartis AG stock forecast
Novartis AG financial statements
Average Price Target
$120.5
Potential downside: -4.06%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 13.93B | 2.31B | 16.62% |
|---|---|---|---|
| Sep 2023 | 12.09B | 1.76B | 14.56% |
| Dec 2023 | 11.77B | 8.48B | 72.01% |
| Mar 2024 | 11.82B | 2.68B | 22.72% |
| 2024-10-29 | 1.94 | 2.06 |
|---|
7.67%
Yield TTM
| Payout ratio | 43.31% |
|---|
| 2019 | 3.24% |
|---|---|
| 2020 | 3.43% |
| 2021 | 3.97% |
| 2022 | 4.01% |
| 2023 | 3.46% |
| Jun 2023 | 110979000000 | 59.04B | 53.21% |
|---|---|---|---|
| Sep 2023 | 112697000000 | 74.45B | 66.06% |
| Dec 2023 | 99945000000 | 53.19B | 53.22% |
| Mar 2024 | 94334000000 | 54.57B | 57.86% |
| Jun 2023 | 3.57B | -1.05B | -3.63B |
|---|---|---|---|
| Sep 2023 | 5.37B | -2.21B | -832M |
| Dec 2023 | 2.54B | -1.76B | -607M |
| Mar 2024 | 2.26B | -898.99M | -5.16B |
Novartis AG alternative data
| Aug 2023 | 101,703 |
|---|---|
| Sep 2023 | 103,000 |
| Oct 2023 | 103,000 |
| Nov 2023 | 101,703 |
| Dec 2023 | 101,703 |
| Jan 2024 | 101,703 |
| Feb 2024 | 76,057 |
| Mar 2024 | 76,057 |
| Apr 2024 | 76,057 |
| May 2024 | 76,057 |
| Jun 2024 | 76,057 |
| Jul 2024 | 76,057 |
Novartis AG other data
9.19%
-0.14%
of NVS is owned by hedge funds
1.09K
-24
207.78M
-3.05M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 15 Dec 2021 Issue date: 8 Sep 2022 |
Application Filling date: 24 Sep 2020 Issue date: 8 Sep 2022 |
Application Filling date: 18 Dec 2019 Issue date: 8 Sep 2022 |
Grant Utility: Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof Filling date: 18 Jun 2020 Issue date: 6 Sep 2022 |
Grant Utility: Process and intermediates Filling date: 25 Jun 2019 Issue date: 6 Sep 2022 |
Grant Utility: Polyomavirus neutralizing antibodies Filling date: 28 Nov 2018 Issue date: 6 Sep 2022 |
Grant Filling date: 13 Jun 2017 Issue date: 6 Sep 2022 |
Grant Filling date: 10 May 2017 Issue date: 6 Sep 2022 |
Application Filling date: 19 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 13 May 2022 Issue date: 1 Sep 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 23 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 31 Jan 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 24 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 18 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Vasant Narasimhan (1976) Chief Executive Officer | $5,080,000 |
Mr. Richard Saynor (1967) Chief Executive Officer of Sandoz | $3,800,000 |
Dr. James E. Bradner M.D. (1972) Pres of Novartis Institutes for Biomedical Research | $3,200,000 |
Ms. Susanne Schaffert Ph.D. (1967) Pres of Novartis Oncology | $3,010,000 |
Mr. Harry Kirsch (1965) Chief Financial Officer | $2,680,000 |
Dr. John Tsai (1967) Head of Global Drug Devel. & Chief Medical Officer | $2,300,000 |
Ms. Marie-France Tschudin (1971) Pres of Novartis Pharmaceuticals | $2,100,000 |
Mr. Steffen Lang Ph.D. (1967) Global Head of Technical Operations | $2,020,000 |
Mr. Robert Weltevreden (1969) Head of Customer & Technology Solutions | $1,570,000 |
Dr. Klaus Moosmayer Ph.D. (1968) Chief Ethics, Risk & Compliance Officer | $1,330,000 |
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector
Why Novartis Is Still A 'Buy' After 15% Surge
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Stock Picks From Seeking Alpha's June 2025 New Analysts
Merck & Co.: A Pharma Titan At A Discount
Merck: Don't Let Today's Bargain Opportunity Pass You By
Novartis: A SWAN Worth Owning
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
-
What's the price of Novartis AG stock today?
One share of Novartis AG stock can currently be purchased for approximately $125.6.
-
When is Novartis AG's next earnings date?
Novartis AG is estimated to report earnings on Monday, 27 Oct 2025.
-
Does Novartis AG pay dividends?
Yes, Novartis AG pays dividends and its trailing 12-month yield is 7.68% with 43% payout ratio. The last Novartis AG stock dividend of $0 was paid on 15 Mar 2021.
-
How much money does Novartis AG make?
Novartis AG has a market capitalization of 190.36B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 9.97% to 46.66B US dollars. Novartis AG earned 14.85B US dollars in net income (profit) last year or $2.06 on an earnings per share basis.
-
What is Novartis AG's stock symbol?
Novartis AG is traded on the NYSE under the ticker symbol "NVS".
-
What is Novartis AG's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Novartis AG?
Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Novartis AG's key executives?
Novartis AG's management team includes the following people:
- Dr. Vasant Narasimhan Chief Executive Officer(age: 49, pay: $5,080,000)
- Mr. Richard Saynor Chief Executive Officer of Sandoz(age: 58, pay: $3,800,000)
- Dr. James E. Bradner M.D. Pres of Novartis Institutes for Biomedical Research(age: 53, pay: $3,200,000)
- Ms. Susanne Schaffert Ph.D. Pres of Novartis Oncology(age: 58, pay: $3,010,000)
- Mr. Harry Kirsch Chief Financial Officer(age: 60, pay: $2,680,000)
- Dr. John Tsai Head of Global Drug Devel. & Chief Medical Officer(age: 58, pay: $2,300,000)
- Ms. Marie-France Tschudin Pres of Novartis Pharmaceuticals(age: 54, pay: $2,100,000)
- Mr. Steffen Lang Ph.D. Global Head of Technical Operations(age: 58, pay: $2,020,000)
- Mr. Robert Weltevreden Head of Customer & Technology Solutions(age: 56, pay: $1,570,000)
- Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer(age: 57, pay: $1,330,000)
-
How many employees does Novartis AG have?
As Jul 2024, Novartis AG employs 76,057 workers.
-
When Novartis AG went public?
Novartis AG is publicly traded company for more then 28 years since IPO on 7 Nov 1996.
-
What is Novartis AG's official website?
The official website for Novartis AG is novartis.com.
-
How can i contact Novartis AG?
Novartis AG can be reached via phone at +41 61 324 11 11.
-
What is Novartis AG stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Novartis AG in the last 12 months, the avarage price target is $120.5. The average price target represents a -4.06% change from the last price of $125.6.
Novartis AG company profile:
Novartis AG
novartis.comExchange:
NYSE
Full time employees:
76,057
Industry:
Drug Manufacturers - General
Sector:
Healthcare
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Lichtstrasse 35
Basel, 4056
Basel, 4056
CIK: 0001114448
ISIN: US66987V1098
CUSIP: 66987V109
